Kevin Lundquist.
ISELIN, N.J.—Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of Lytenava (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, has announced the appointment of Kevin Lundquist as chief financial officer (CFO), effective September 1, 2026. Following the recent FDA approval of Lytenava, an ophthalmic formulation of bevacizumab produced in the U.S. for the treatment of wet AMD, Lundquist will lead the development of the financial and operational structure required to advance the upcoming U.S. commercial launch, according to the announcement.
In connection with Lundquist’s appointment, Lawrence Kenyon will step down as CFO, effective September 1, 2026, and will continue to support the company as a non-executive employee through September 30, 2026, the company said.
“FDA approval of Lytenava fundamentally changes the opportunity in front of Outlook Therapeutics, and Kevin is exactly the caliber of executive we need as we enter this next phase,” said Bob Jahr, CEO of Outlook Therapeutics. “He brings an exceptional combination of financial and operational leadership, capital markets expertise, and experience leading finance functions across large-scale pharmaceutical and commercial organizations.”
Jahr continued, “Importantly, Kevin has firsthand experience building the financial and operational infrastructure needed to support approved commercial products. As we turn our focus toward executing on the opportunity created by Lytenava’s approval, Kevin will be instrumental in helping us build a disciplined, scalable organization positioned to drive long-term growth and shareholder value.”
With the launch of Lytenava planned before the end of calendar 2026, the company recently said it is expanding payer engagement, scaling commercial supply, and building a focused commercial organization informed by feedback from retina physicians, practices, and other key stakeholders.
Lundquist brings more than 20 years of corporate finance and capital markets experience across the pharmaceutical, biotechnology, medical technology, and manufacturing industries. He has experience leading finance organizations for both public and private equity-backed companies, including commercial-stage businesses, and has direct experience supporting IPOs, commercial operations, SEC reporting, investor relations, capital raising, mergers and acquisitions, treasury, and financial infrastructure. He most recently served as CFO of CapsoVision, Inc., a commercial-stage medical technology company.
“This is an extraordinary time to join Outlook Therapeutics,” said Lundquist. “Lytenava has the potential to address an important need in retinal care, and FDA approval provides the foundation from which to build its U.S. market presence. I am excited to work alongside Bob and the entire Outlook team to help translate that opportunity into meaningful commercial growth. My priorities will include maintaining financial discipline, allocating capital toward the company’s highest-value opportunities, and ensuring Outlook has the resources and capabilities needed to execute its U.S. launch strategy.”
Additionally, Outlook Therapeutics announced that the compensation committee of its board of directors approved the issuance of an option to purchase 500,000 shares of common stock to Lundquist in accordance with Nasdaq Listing Rule 5635(c)(4), as a material inducement to Lundquist’s start of employment with Outlook Therapeutics.
